However, anti-PD-L1 antibody, atezolizumab, provide clinical benefit even in the subgroup of cancer patients where PD-L1 is low or undetectable on tumor cells and tumor-infiltrating immune cells (TC0/IC0). In this study, we investigated the mechanism of action by which PD-L1-negative tumors...
Although the PD-L1 molecule is involved in the mechanism of action of anti-PD-1 therapies, other aspects of adaptive immunity, namely T cells, may be more useful in predicting response8. T cells can be classified according to their activation and differentiation status, which capture the activi...
This beta sheet presents an epitope surface that significantly overlaps with the PD-1 binding interface, consistent with a desired PD-1 competitive mechanism of action for the antibody. Surface plasmon resonance screening of mutant PD-L1 variants confirmed that the region identified by HDX-MS is ...
Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. Expert Opin. Drug Deliv. 18, 187–203 (2021). Article CAS PubMed Google Scholar Wang, F. H. et al. Efficacy, safety, and correlative biomarkers of toripalimab ...
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793–800 (2002). Article CAS Google Scholar Sznol, M. & Chen, L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin. Cancer Res....
Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. If used during pregnancy, or if the patient becomes pregnant during treatment, apprise the patient of the potential hazard to a fetus. Advise females of reproductive potential t...
3.6. Mechanism of action of chemotherapy plus immunotherapy After the therapeutic efficiency was confirmed, we studied the mechanism of action of chemotherapy combined with immunotherapy. Studies have indicated that PTX can induce ICD, enhance the release of immunogenic signal molecules such as CRT, pro...
Competitive enzyme-linked immunosorbent assay (ELISA) was employed to detect the biological activity of anti-PD-1 antibody [15], [16], but it was not able to reflect the mechanism of action (MOA) of the anti-PD-1 antibody due to the lack of cells in the assay. The two classical ...
Blank, et al., “Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.” Cancer Immunology, Immunotherapy (2005); 54(4): 307-314. Boyd and Crowe Jr., “Deep sequencing and human antibody repertoir...
Without wishing to be bound by any particular theory or mechanism of action, it is believed that the PD-L1 binding agents according to this embodiment cause PD-L1 internalization upon binding, and remain bound to PD-L1 during internalization resulting in internalization of the binding agent along...